

Mouse LOX-1/OLR1 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1564

DESCRIPTION			
Species Reactivity	Mouse		
Specificity	Selected for its ability to block receptor-ligand interaction in a functional ELISA assay. In Western blots, approximately 5% cross-reactivity with recombinant human LOX-1 is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse LOX-1 (R&D Systems, Catalog # 1564-LX) Arg60-lle363 Accession # AAG44998		
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.		

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 μg/mL	Recombinant Mouse LOX-1/OLR1 (Catalog # 1564-LX)
Blockade of Receptor-ligand Interaction		, 1 - 4 μg/mL of this antibody will block 50% of the binding of 1 μg/mL of biotinylated AGE-combinant mouse LOX-1 coated at 5 μg/mL (100 μL/well). At 10 μg/mL, this antibody will ding.

PREPARATION AND STORAGE		
Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.	

BACKGROUND

Lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1), also known as oxidized low-density-lipoprotein receptor-1 (OLR-1), is a type II transmembrane receptor belonging to the C-type lectin family (1). It also belongs to the functionally defined scavenger receptor (SR) superfamily, whose members share the common ability to bind and internalize modified forms of Low Density Lipoproteins (LDL) (2 - 4). LOX-1 is the first member of the class E scavenger receptor subfamily (SR-E). It binds and supports the internalization of multiple structurally unrelated macromolecules including oxidized LDL, advanced glycation end products (AGE), activated platelets, bacteria, apoptotic or aged cells, and heat shock proteins (5 - 7). LOX-1 has also been implicated as an intestinal receptor involved in the transcytosis of pancreatic bile salt-dependent lipase (8). The mouse LOX-1 gene encodes a 363 amino acid (aa) residue protein with a short N-terminal intracellular domain, a transmembrane domain, triple repeats of an extracellular stalk/neck region followed by a C-type lectin-like domain (CTLD) (11). The CTLD, which is required for ligand recognition, contains the six conserved cysteine residues present in all C-type lectins, but lacks the Ca²⁺-binding residues found in classical C-type lectins. LOX-1 can be detected on activated endothelial cells, vascular smooth muscle cells, macrophages, intestinal cells and dendritic cells (6 - 8). The expression of LOX-1 is induced by proinflammatory or proatherogenic stimuli, as well as by oxidized LDL itself and hemodynamic or oxidative stress. LOX-1 exists on the cell surface as covalent homodimers, which can further associate into non-covalent-linked oligomers (9). Cell surface LOX-1 can also be cleaved by yet unidentified proteases to release the soluble LOX-1 extracellular domain (6). Binding and endocytosis of oxidized LDL by LOX-1 induces oxidative stress, activates NFkB, and upregulates the expression of monocyte chemoattractant protein-1 and matrix metalloproteases (5

References:

- 1. Sawamura, T. et al. (1997) Nature 386:73.
- 2. Daugherty, A. (2000) Curr. Opin. Cardiovasc. Pulm. Ren. Invest. Drugs. 2:223.
- 3. Platt, N. and S. Gordon (2001) J. Clin. Invest. 108:649.
- 4. Platt, N. and S. Gordon (1998) Chem. Biol. **5**:R193.
- 5. Jono, T. *et al.* (2002) FEBS Lett. **511**:170.
- 6. Kume, N. *et al.* (2001) Curr. Opin. Lipidol. **12**:419.
- Delneste, Y. et al. (2002) Immunity 17:353.
- 8. Bruneau, N. et al. (2003) Mol. Biol. Cell 14:2861.
- 9. Xie, Q. et al. (2004) DNA and Cell Biol. 23:111.
- 10. Chen, J. et al. (2003) Circ. Res. 94:370.
- 11. Hoshikawa, H. et al. (1998) Biochem. Biophys. Res. Comm. 245:841.

Rev. 2/6/2018 Page 1 of 1

